[
    [
        {
            "time": "2021-06-15",
            "original_text": "Beigene Surges Closer To Breakout On $2.2 Billion Deal With Novartis",
            "features": {
                "keywords": [
                    "Beigene",
                    "Surges",
                    "Breakout",
                    "$2.2 Billion",
                    "Novartis"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-06-15",
            "original_text": "Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene",
            "features": {
                "keywords": [
                    "Novartis",
                    "In-Licenses",
                    "Anti-PD-1",
                    "Antibody",
                    "BeiGene"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-06-15",
            "original_text": "The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue",
            "features": {
                "keywords": [
                    "Daily Biotech Pulse",
                    "GSK",
                    "Vir",
                    "COVID-19",
                    "Antibody Study",
                    "Novartis",
                    "In-Licenses",
                    "BeiGene",
                    "Cancer Drug",
                    "Earnings Preannouncements"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        }
    ]
]